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Abstract
Background: Around 17 % of people eligible for UK cardiac rehabilitation programmes following an acute coronary
syndrome report moderate or severe depressive symptoms. While maximising psychological health is a core goal of
cardiac rehabilitation, psychological care can be fragmented and patchy. This study tests the feasibility and
acceptability of embedding enhanced psychological care, composed of two management strategies of proven
effectiveness in other settings (nurse-led mental health care coordination and behavioural activation), within
the cardiac rehabilitation care pathway.
Methods/Design: This study tests the uncertainties associated with a large-scale evaluation by conducting an
external pilot trial with a nested qualitative study. We aim to recruit and randomise eight comprehensive cardiac
rehabilitation teams (clusters) to intervention (embedding enhanced psychological care into routine cardiac
rehabilitation programmes) or control (routine cardiac rehabilitation programmes alone) arms. Up to 64 patients
(eight per team) identified with depressive symptoms upon initial assessment by the cardiac rehabilitation team
will be recruited, and study measures will be administered at baseline (before starting rehabilitation) and at 5 months
and 8 months post baseline. Outcomes include depressive symptoms, cardiac mortality and morbidity, anxiety,
health-related quality of life and service resource use. Trial data on cardiac team and patient recruitment, and the
retention and flow of patients through treatment will be used to assess intervention feasibility and acceptability.
Qualitative interviews will be undertaken to explore trial participants’ and cardiac rehabilitation nurses’ views and
experiences of the trial methods and intervention, and to identify reasons why patients declined to take part in
the trial. Outcome data will inform a sample size calculation for a definitive trial.
Discussion: The pilot trial and qualitative study will inform the design of a fully powered cluster randomised
controlled trial to evaluate the effectiveness and cost-effectiveness of the provision of enhanced psychological
care within cardiac rehabilitation programmes.
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Background
Prevalence of depression and associated outcomes for
patients with acute coronary syndromes
Major depression is common among people with coron-
ary heart disease. Most research has focused on patients
with acute coronary syndromes (ACS), among whom
prevalence rates for depression are around 20 % as de-
termined by studies using rigorous clinically structured
research interviews [1]. Rates of depression have also
been shown to be elevated in individuals following cor-
onary artery bypass grafting [2], patients with unstable
angina [3] and patients with chronic heart failure [4].
These rates greatly exceed those seen in the UK general
population (2.6 % [5]), suggesting that the associations
between coronary disease and depression may be causal
(direct or indirect).
The nature of the association between depression and
coronary disease is complex. Depression can predate an
ACS, approximately doubling the risk of subsequent in-
cident ACS [6, 7], and worsen associated heart failure
[8] or cardiac mortality [9]. Depression that predates an
ACS is predicted by younger age, female sex, lack of so-
cial support, ongoing life difficulties and a past psychi-
atric history [10]; these are similar to risk factors for
depression in the general population. Depressive symp-
toms may occur after an ACS, so-called ‘new onset’
depression [10]; approximately 20 % of individuals after
a recent myocardial infarct (MI) develop depressive
symptoms in the 12 months following their cardiac
event. ‘New onset’ depression is not associated with the
usual risks for depression, but is predicted by negative
illness representations relating to the ACS and ongoing
cardiac symptoms [10, 11]. Mechanisms underpinning
the association between depressive symptoms and poor
cardiovascular outcomes may include biological and be-
havioural processes, or may be confounded by shared
genetic vulnerability, environmental stresses, or persev-
erative negative cognitive processes [12].
Depression among people with an established ACS is
an important predictor of negative medical outcomes
including poorer health-related quality of life [13, 14],
greater morbidity and mortality [15–18], greater use of
routine and unscheduled health care [19, 20] and
greater health care costs [21]. Some studies have indi-
cated that the timing of onset of depressive symptoms
with regards to cardiac-related hospitalisation may be
important in determining health outcomes. In particu-
lar, ‘new onset’ depression that develops following an
MI has the greatest association with subsequent mor-
tality [21–24]. It remains unclear, however, whether
‘new onset’ depression is particularly ‘cardiotoxic’ or
whether its apparent associations with poor cardiac
outcomes is confounded [23] by, for example, the se-
verity of the underlying cardiac disease or due to a re-
tention bias, with patients suffering with premorbid
depression dying before reaching follow-up [9].
Usual care for patients with cardiac disease and
depression
In the UK, the NHS routinely offers multidisciplinary
cardiac rehabilitation (CR) to patients who experience
an acute cardiac event. CR follows a seven-stage stand-
ard patient care pathway (stages 0–6, Fig. 1) [25, 26].
Guidance on the recommended content of standard
care is published by the British Association for Cardio-
vascular Prevention and Rehabilitation (BACPR) [26].
Core components include: education; exercise and
physical activity; diet and weight management; medical
management; and psychological support. In 2010–2011
a national CR audit [27] identified 290 operationally
distinct, locality-based comprehensive cardiac rehabili-
tation programmes (CCRPs; stages 2–5). These teams
undertake patient assessments (including mental health
status), then generate and implement CR care plans.
Patient attrition across the CR pathway is high. Al-
though around 17 % of patients screen positive for depres-
sive symptoms when attending an initial, locality-based
CCRP assessment (stages 2–3), around half of these will
not proceed to CCRP. Despite the burden of depressive
symptoms, only 10 % of CR services report direct psych-
ology input [27] and patients’ depression usually remains
untreated [28]. Locally agreed referral protocols provid-
ing for access to psychological care at either the tertiary
(stage 1) or community (stages 2–5) level may be
agreed. However, the precise content of such protocols
and the consistency of their implementation remain un-
clear from audit data.
While it would appear that structured management of
depressive symptoms is not routinely provided in CR,
patients can access mental health care through existing
care pathways for depression [29–31]. Effective care in-
cludes mental health care coordination, which is often
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managed in primary care and involves the use of stepped
care algorithms, and access to psychological or pharma-
cological interventions of proven effectiveness.
In general populations, cognitive behavioural therapy
(CBT) and antidepressant medication (ADM) are the
two treatments with most evidence of effectiveness, and
both are recommended by the National Institute for
Clinical Excellence (NICE) [29, 30]. However, there are
problems with ADM, which include side-effects, poor
patient adherence and relapse risk on ADM discontinu-
ation. Service-user organisations and policy think tanks
advocate greater availability of psychological therapies,
which many people prefer [32]. CBT, which is of similar
efficacy to ADM [33], has several advantages: it is con-
sistent with many service users’ preferences for non-
pharmacological treatment, and it modifies the illness
trajectory as its benefits continue after the end of treat-
ment by teaching skills to prevent depressive relapse in
the long term. However, CBT has several potential dis-
advantages. Not all patients may engage or adhere to
CBT, due to a multiplicity of reasons (e.g. burden of
homework, feelings of confusion or upset at revisiting
painful or difficult emotions and situations during ther-
apy) [34]. CBT requires extensive training to deliver
competently, and is typically offered only by specialist
CBT therapists. The high costs of training and employ-
ing sufficient therapists may limit attempts to access
CBT. The recent ‘Improving Access to Psychological
Therapies’ (IAPT) [35, 36] programme in England has
done much to enhance access and recovery rates which
are at approximately 50 %. However, IAPT does not
reach into specialist CR settings where brief and access-
ible psychological treatments may have much to offer.
One such psychological treatment is that of Behav-
ioural Activation (BA). BA is postulated to alleviate
depression by focusing directly on changing behaviour
based on behavioural theory [37]. This theory states
that depression is maintained by avoidance of normal
activities. As people withdraw and disrupt their basic rou-
tines, they become isolated from positive reinforcement
opportunities in their environment. They may then end
up stuck in a cycle of depressed mood, decreased activity
and avoidance [37]. BA systematically disrupts this cycle,
initiating action in the presence of negative mood, when
people’s natural tendency is to withdraw or avoid [38]. Al-
though CBT incorporates some behavioural elements,
these focus on initiating behavioural experiments to test
specific beliefs. In contrast, BA targets avoidance from a
contextual and functional approach not found in CBT,
focusing on understanding the function of behaviour
and replacing it accordingly. BA also explicitly priori-
tises the treatment of negatively reinforced avoidance
and rumination. Furthermore, the BA rationale is easier
to understand and operationalise for both patients and
mental health workers than CBT, where activity is also
increased but the primary techniques focus on chan-
ging maladaptive beliefs [39]. Its focus on context and
functioning is also closely aligned to the ethos of CR
services. The relative simplicity of BA treatment makes
it relatively straightforward to train nurses without mental
health training in its application [40–42]. The study team
includes the expertise in respect of the design, training,
and delivery of a BA-based intervention [41–43].
Rationale for current research
There is a lack of clear evidence of efficacy for conven-
tional treatments for depression in patients with ACS.
Trials of the antidepressants sertraline, citalopram and
mirtazapine have shown small or no effect on depres-
sion among patients with ACS [44–46]. Efficacy of
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Fig. 1 UK cardiac rehabilitation care pathway. UK Department of Health’s ‘0–6 Stage Patient Pathway of Care’ for cardiac rehabilitation services [83]
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psychological treatments, which are usually preferred
by patients, remains unclear. Recent systematic reviews
[47, 48] report modest but significant reductions in de-
pression for patients with coronary disease receiving
psychological treatment, although the methodological
quality of studies selected is such that it precludes firm
conclusions regarding which treatments are most ef-
fective. Several high-quality randomised controlled tri-
als (RCTs) in patients with ACS and depression have
not confirmed the benefits of psychological therapy in
this population. In the large ENRICHD trial, CBT plus
citalopram led to very small improvements in depres-
sion that were not sustained [49]. Similarly, the CRE-
ATE trial found that interpersonal psychotherapy was
no better than standard care [44]. In contrast, the
CODIACS Vanguard trial RCT [50, 51] found that a pa-
tient preference intervention (management options
available included problem-solving therapy delivered by
a centralised service offered via phone or the web,
ADM, both or neither) combined with a stepped care
algorithm significantly improved depressive symptoms
at 6-months post randomisation. However, these results
must be interpreted with caution as the sample size
was small (n = 150), and no conclusions can be drawn
regarding the effectiveness of individual therapeutic
options available as part of the preference intervention.
No trials to date have evaluated the effectiveness of BA
in patients with an ACS and ‘new onset’ depression.
Most intervention studies have recruited participants
immediately following an acute cardiac event, and the
complexity of depression in that period may have con-
tributed to the lack of treatment response. The reasons
for the limited benefits of conventional depression
treatments in patients with coronary disease are not
clear. First, depression that starts after an ACS is differ-
ent from depression in the general population. Post-
ACS depression does not have the usual risk factors as
seen in the general population, but is associated with
ongoing cardiac symptoms, and increased concerns
about health [10, 11], which may act to reduce the re-
sponse to conventional treatment [45]. Second, conven-
tional psychological treatments, such as CBT, that
encourage recall of past experience and that challenge
maladaptive thoughts, may be too traumatic for people
who have suffered a recent, serious threat to life. Third,
conventional psychological therapies available through
IAPT are considered expensive and may not be widely
available to patients with CHD. Indeed, a recent quali-
tative study of patients [52] concluded that manage-
ment of depression should be embedded within CR
teams rather than as another source of referral. UK CR
programmes experience significant patient attrition at
each stage of the rehabilitation pathway, with over half
of patients dropping out before locality-based CCRP
commences. Given this attrition, for the 17 % of pa-
tients with depressive symptoms who actually attend at
least one assessment with a CCRP, ‘another outward re-
ferral’ for psychological care may simply be a further
barrier to accessing timely care. If a low-intensity psy-
chological treatment, such as BA, has the potential to
be safely and effectively [38, 40–42, 53, 54] embedded
within the CCRP, this could holistically tackle the
depressive symptoms at the same time as physical re-
habilitation as part of patient case management. Simi-
larly, acknowledging that attrition from rehabilitation is
high even in patients who attend an initial CCRP as-
sessment, we also believe that any attempt to enhance
psychological care should include training CR nurses
(who routinely screen for depressive symptoms) to apply
evidence-based referrals for those who elect not to attend
rehabilitation. Such mental health care coordination will
also be in place for patients completing CCRP (including
BA), but whose symptoms do not respond.
Study aims and objectives
The overarching aim of this pilot study is to test the
methods and procedures required to undertake a fully
powered evaluation of the clinical effectiveness and cost-
effectiveness of CR teams implementing an enhanced
psychological care intervention (EPC) for patients with
‘new onset’ depressive symptoms using CR services com-
pared with CR services delivering usual care. Specific ob-
jectives are:
1. To quantify the flow of patients (i.e. eligibility,
recruitment and attrition rates) from the cardiac
event to the 8-month follow-up for patients entering
the CR care pathway, and in particular, to document
the flow of those patients who agree to take part in
the pilot trial
2. To collect participant outcome data in order to
estimate the standard deviation for continuous
outcomes to inform sample size calculations for a
definitive trial
3. To establish the data collection methods required
to support a definitive economic evaluation
4. To gather qualitative evidence from patients
(including participants who did or did not adhere
to the EPC, and those who declined to take part in
the trial) and CR nurses on the acceptability of EPC,
and on the appropriateness of study methods and
procedures. Information will also be sought on the
content of usual psychological care within CR teams
Methods/Design
Consistent with Medical Research Council (MRC) guid-
ance [55] a two-phase study was planned, including a
mixed-method feasibility study, followed by a pilot
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cluster randomised controlled trial (RCT) and nested
qualitative interview study.
Pre-pilot feasibility study
Although the focus of this paper is to report the design
of the pilot trial, a brief summary of the feasibility study
is provided here. The feasibility study (completed March
2015 prior to commencing the pilot trial) employed a
mixed-method design to develop and assess an EPC
intervention and to undertake preliminary testing of its
implementation. Observations of usual care, a before
and after observational study, and qualitative interviews
with staff and service users were undertaken. The EPC
intervention was developed working with four nurses
from three NHS CCRP services (stages 2–5; see Fig. 1)
from South West England. Nine eligible patients (i.e. in-
dividuals with ‘new onset’ depression) were recruited,
and both staff and patients were invited to comment on
the feasibility and acceptability of implementing and/or
experiencing EPC. Additional CR process data was re-
corded, including participant attendance at, and adher-
ence with the CCRP with embedded EPC. The findings
from this feasibility study were used to refine and de-
velop the EPC intervention and the pilot trial methods.
Specifically, qualitative and observational data, consid-
ered along with findings arising from discussions with
lay representatives, identified the need to reduce the
intensity of the BA component of the EPC delivered by
CR nurses operating within the context of routine care.
The EPC intervention to be delivered in the pilot study
will thus retain the nurse acting as a mental health care
coordinator, using clearly defined clinical decision-
making points and applying evidence-based referral
pathways, with the BA component delivered as a
participant-led BA intervention, actively supported by
the CR nurse.
Pilot cluster randomised controlled trial
An external pilot cluster RCT [56, 57] will be undertaken,
including the piloting of economic data collection, and a
qualitative interview study. A Consolidated Standards of
Reporting Trials (CONSORT) diagram describing the flow
of participants through the study is presented in Fig. 2.
Trial interventions
Usual care (control) intervention
Usual care is defined here as the standard CR rehabilita-
tion commencing at the point of assessment undertaken
by a CR specialist nurse from a locality-based CCRP
(stages 2–3). Of patients invited to attend CCRP, around
41 % attend structured sessions within 2–10 weeks (stage
4) [27]. Treatment as usual in CCRPs typically includes
intensive rehabilitation for 1–2 sessions per week for ap-
proximately 8 weeks. Sessions generally last around
2 hours and include structured exercise, education (e.g.
managing lifestyle and cardiac risk) and some psycho-
logical input (e.g. relaxation, stress management) in order
to meet the core standards of care described by BACPR
[26]. On exiting CCRP, a final assessment (stage 5) and
discharge arrangements will be made to community ser-
vices (stage 6).
There is debate as to what constitutes standard psy-
chological care within CR [27], and a core objective is to
clarify this definition. National audit data found that psy-
chological expertise within locality-based CCRPs is un-
common (< 10 %). In the feasibility study, some patients
with depressive symptoms were referred to a clinical
psychologist. However, no systematic approach was rou-
tinely adopted to identify patients as being suitable for
referral. The decision was pragmatic, being based on a
combination of reviewing depression scores obtained in
standard CCRP assessments, discussions with patients,
and clinical judgment regarding who might benefit from
referral. Informal discussions with mental health special-
ists and CR staff suggest that there is considerable vari-
ation in local CCRP protocols across the UK.
Enhanced psychological care (treatment) intervention
Based on our feasibility findings, we propose to embed
EPC within existing CR care pathways, with referrals to
existing community mental health services as appropri-
ate. CR nurses from operationally distinct ‘clusters’ –
locality-based CCRPs (see Fig. 1, stages 2–5) will be
trained to deliver EPC based on a nurse training man-
ual developed and refined during the feasibility study.
The CR nurse will implement mental health care co-
ordination [29, 30], including an embedded participant-
led BA programme [38, 40–42, 53, 54]. Pre-existing
participant and nurse training materials used by the co-
applicant (DAR), in previous research, were adapted
during the feasibility phase following an iterative
process of qualitative data collection with trainers, CR
nurses and patients, combined with lay and clinical ad-
visors’ feedback.
To deliver mental health care coordination, CR
nurses will apply clinical decision-making rules based
on current best practice [29, 30], matching the intensity
of treatment with participant preferences for mental
health care. All patients referred to a locality-based
CCRP and who agree to undertake an initial assessment
(stages 2–3), will be routinely screened for depressive
symptoms using the Patient Health Questionnaire
(PHQ-9) [58, 59]. This tool assesses the nine Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV)
depression criteria, with individuals scoring 10 or more
(out of a possible score of 27) during their initial CR as-
sessment deemed eligible for inclusion.
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On identifying an eligible individual, the nurse will
explain what evidence-based treatment options are
available. This includes BA self-help materials sup-
ported by the nurse, GP referral, referral to local IAPT
services, and/or referral to specific cardiac patient psy-
chological support services where available. Nurses will
coordinate care by monitoring symptoms of depression
and anxiety, assessing risk to self or others and agreeing
a plan of care with participants that may include BA
and/or referral to GP, IAPT or other therapeutic agen-
cies as described above.
As part of this care coordination protocol, all partici-
pants will be offered nurse-supported self-help using a par-
ticipant BA manual. The self-help BA manual consists of a
structured programme aimed at enabling participants to
re-engage with sources of positive reinforcement from
their environment and to develop future strategies for
managing their depressive symptoms. The manual adopts
a functional analytical approach, aiming to help the partici-
pant develop an understanding of behaviours that might
interfere with meaningful, goal-oriented behaviours (e.g.
negative avoidant behaviours). The manual also explains
CCRPs agree
to be randomised
(8 CCRPs) 
(8 CCRPs)
Allocated to enhanced  
psychological care 
intervention
5 CCRPs
n patients recruit
Allocated to usual care 
control
3 CCRPs
n patients recruited 
5 month follow-up
m CCRPs
n patients 
5 month follow-up
m CCRPs
n patients 
8 month follow-up
m CCRPs
n patients 
8 month follow-up
m CCRPs
n patients 
CCRs *approached
CCRPs randomised
Fig. 2 Consolidated Standards of Reporting Trials (CONSORT) diagram. CONSORT diagram (with cluster extension) for the CADENCE pilot
randomised controlled trial (RCT)
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how to self-monitor mood, and then to identify patterns of
behaviour associated with their depression. Participants
are encouraged to develop alternative behaviours which
are goal- orientated, targeting routine, pleasurable, and ne-
cessary activities, and activity scheduling of these identified
behaviours.
Although our pilot intervention involves a participant-
led self-help BA manual, the CR nurses will actively sup-
port participants. The CR nurses will attend a 2-day
training course delivered by experienced mental health
practitioners, during which they will receive training on
the key techniques of mental health care coordination,
managing safety and risks, and BA. This training will
allow nurses to actively support participants during care
coordination and as they work through the BA manual
alongside their CR programme. Nurses will also be pro-
vided with a session-by-session guide, detailing the types
of care coordination tasks which might be relevant for
participants as they move through their 6–8 week struc-
tured programme (Additional file 1). This guide is flex-
ible to accommodate participant preferences for care.
Nurses who are delivering EPC to study participants will
also receive bi-weekly clinical supervision by an experi-
enced mental health practitioner.
For those participants who complete CCRP (stage 5),
structured details of the care received will be sent to
their GP. All participants, including those receiving BA
and whose depressive symptoms do not respond, will be
given an opportunity to review their management op-
tions with the nurse. Here, treatment response is defined
as achieving a minimally important clinical difference
(MICD) for the PHQ-9 equivalent to a 5-point reduction
in score [60]. It is important to note, however, that some
people who achieve such a MICD may remain above the
PHQ-9 diagnostic threshold (≥ 10). As part of their care
coordination, these individuals will be referred for con-
tinuing mental health management.
Randomisation and allocation concealment
An external pilot cluster RCT [56, 57] will be under-
taken, seeking to recruit and randomise eight CCRPs
(clusters) to a treatment or a control arm in a 5:3 ratio.
The randomisation ratio was informed by data emer-
ging from our feasibility study, including the need to
ensure that sufficient nurses and patients have EPC ex-
posure to support the aims of the qualitative process
evaluation. Randomisation will be conducted using the
stratifying variables of CR team setting (hospital-based,
community-based, or mixed hospital and community),
and monthly throughput of new patients assessed for
CR at stages 2–3, facilitating division into small and
large teams. Team setting has been selected as a strati-
fying variable because our feasibility study suggested
that teams working in hospital and community settings
may encounter different resource issues that could
affect the delivery of EPC. Throughput of new patients
into CR services has been selected as a stratifying vari-
able, as this is an indicator of team workload, and will
ensure that sufficient participants are recruited into
each trial arm.
Randomisation will be carried out by a statistician, in-
dependent from the researchers recruiting CR teams,
using computer-generated random numbers. A cluster
randomised design, as opposed to individual participant
randomisation, is essential to avoid contamination be-
tween trial arms (i.e. intervention participants coming
into direct contact with controls and sharing aspects of
their treatment). Our EPC intervention involves training
CR nurses to apply mental health care coordination with
embedded participant-led BA. Once trained, it would be
very difficult operationally for the nurse to apply structured
care coordination to only a subset of eligible participants
(as would be required with individual randomisation).
Settings and study population
CCRP recruitment procedures
Eight locality-based CCRPs in South West England will
be recruited and randomised. Teams who took part in
the feasibility study will be excluded. A two-stage ap-
proach to local CCRP recruitment will be employed. We
will write to the lead CR nurse in each of the 20 oper-
ationally distinct CCRPs in South West England provid-
ing detailed information about the study and inviting
their participation. In each of the geographical areas the
recruitment letter will be co-signed by the trial chief
investigator and the local co-applicant. Each team indi-
cating an interest in participation will receive a briefing
visit, where the trial design and methods will be ex-
plained by the researcher, and the staff will be given an
opportunity to ask questions about what might be in-
volved, before being asked to provide written consent to
participate in the study.
Nurses in teams allocated to the CCRP with EPC
intervention arm will receive EPC and self-harm risk
management training (total of two full days) before they
start to recruit patients. EPC-trained nurses will be su-
pervised regularly by experienced specialist clinicians/
BA practitioners.
Participant eligibility criteria
A pragmatic approach will be adopted, whereby adult
patients (aged 18 years or over) referred for CR based
on local clinical referral protocols will be screened
(stages 2–3) for eligibility. The majority will be individ-
uals previously admitted with an ACS (unstable angina,
non-ST-elevation MI or ST-elevation MI) or following
a coronary revascularization procedure (percutaneous
coronary intervention (PCI), coronary artery bypass
Richards et al. Trials  (2016) 17:59 Page 7 of 15
grafting (CABG)), with or without heart failure [61].
Patients with a new episode of depressive symptoms
identified through nurse screening at the start of CCRP
using the PHQ-9 [58, 62] (score 10 or more) are poten-
tially eligible for inclusion. Patient exclusion criteria in-
clude: individuals reporting having been actively treated
for depression (psychological or drug therapy) within
the previous 6 months, or where there is evidence of al-
cohol or drug dependency, being acutely suicidal, or
having poorly controlled bipolar disorder or psychosis/
psychotic symptoms based on a clinical review (seeking
external confirmation from the GP or other clinicians
as required). No language exclusion will be applied; we
anticipate that the majority of patients will have suffi-
ciently good English language skills to engage with EPC.
However, consistent with routine practice in delivering
psychological therapy, NHS translation resources will be
employed to assist participants where required.
Patient participant recruitment procedure
The CR nurse will apply a structured checklist to ascer-
tain participant eligibility based on our inclusion/exclu-
sion criteria. Eligible participants will be invited to take
part in the trial by the CR nurse, and given brief study
information to take away and review. The nurse will also
ask permission to pass the individual’s contact details on
to the study researcher. The researcher will then contact
the patient within 7 days to discuss study participation
and provide them with a detailed Participant Informa-
tion Sheet. The researcher will arrange to visit the po-
tential participant to obtain written consent and baseline
assessment before the participant commences CCRP
(stage 4). Potential participants will be reminded of their
right to refuse participation, or to withdraw from the
study at any time without it affecting their clinical care.
Sample size
Using UK national audit data (2010–2011), 55,452 pa-
tients (for MI, PCI, CABG) undertook phase 3 CR from
280 teams: an average of 200 patients per team per year.
Assuming 17 % have depressive symptoms [27], this
equates to 35 eligible patients per team each year. The
participant consent rate will be established through
piloting as no relevant UK data, applicable to cluster tri-
als, are available. Two RCTs (individual randomisation)
from the US, exploring psychological/drug therapy in
cardiac rehabilitation settings, observed highly variable
consent rates of 85 % (150/177 – Vanguard CODIACS
study) [51] and 37 % (2481/6854 – ENRICHD study)
[49]. Based on the patient throughput and rates of de-
pressive symptoms observed in our feasibility study,
and an assumed participation rate of 50 %, we aim to
recruit 64 patients through the eight teams in 6 months.
This sample size is sufficient to estimate a follow-up
percentage as low as 50 % with margin of error ±12.8 %
based on the width of the 95 % confidence interval
(CI), and as high as 90 % with a margin of error of ±9.3
% based on the lower bound of the 95 % CI. We do not
plan to use estimates from the pilot of the intra-cluster
(intra-CR team) correlation coefficients (ICCs) for key
outcomes to plan the sample size for the definitive trial
as the pilot sample is small and estimates will be impre-
cise. Using national audit data (2010–2011; 6272 patients;
119 CR teams), we estimate the ICC for depression to be
0.047 (95 % CI: 0.034 to 0.062). This ICC estimate and CI
will be used to inform the sample size calculations for the
definitive trial.
Data collection
Participants in both arms will complete baseline mea-
sures prior to commencing CCRP, and then two face-to-
face follow-up interviews with a researcher at 5 and
8 months post randomisation (Fig. 2). Blinding of pa-
tients, practitioners or researchers extracting data on
study outcomes is not possible in this cluster design, but
the final analysis will be carried out by a statistician who
is blind to treatment allocation. Data will be collected on
process measures, patient-reported outcomes, and re-
source use and costs.
Process measures
Process data relating to participant throughput and
intervention fidelity will be collected.
To ascertain study eligibility and recruitment we will
ask CR nurses to report the numbers of patients: attend-
ing an initial CCRP nurse assessment, the proportion
identified with depressive symptoms during this assess-
ment, the prevalence of ‘new onset’ (as opposed to exist-
ing) depression and the number of patients who were
eligible for study participation. Of eligible patients, we
will describe: the number offered study entry; the num-
ber who later agreed to be contacted by a researcher;
and who subsequently consented to take part and under-
went a baseline interview with a researcher. We will also
capture data on participant socio-demographic charac-
teristics (age, sex, ethnicity/preferred language) and clin-
ical condition resulting in a CR referral to document
how well we have engaged with service users from di-
verse backgrounds, such as non-English speakers.
Intervention fidelity will be established through a
structured notes review documenting the numbers of
participants recruited who do not attend CCRP and the
proportion with documentary evidence of care coordin-
ation in their notes. For participants engaging with the
EPC intervention, we will assess adherence by record-
ing the number of BA sessions offered and the number
of sessions attended, the number of participants with
documentary evidence of care coordination on exiting
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CCRP, and the type of psychological referrals made (if
appropriate).
Participant-reported outcomes measures
Measures are selected on the basis of evidence of their
validity in this population, and to ensure coverage of key
areas from a clinical and patient perspective (with input
from our lay and clinical advisors).
Baseline assessment only This assessment includes
some measures that will not be repeated at follow-up.
The revised clinical interview schedule (CIS-R) [63, 64]
will be administered to ascertain a clinical diagnosis of
depression. This score will not determine study eligibil-
ity, but will allow its comparison to the other patient-
reported measures of depression symptom severity
ascertained using the Beck Depression Inventory (BDI-
II) (described below). Some short questions to ascer-
tain, and account for, participant treatment preferences
[65] will be included. We will extract data from clinical
records (GP, CCRP) relating to known cardiac risk fac-
tors (body mass index (BMI), blood pressure, glycosyl-
ated haemoglobin (HbA1c), lipids, smoking status) as
recorded at the participant’s latest clinical assessment
prior to recruitment.
Baseline and follow-up measures Although we will re-
quest that NHS providers inform us of any participant
deaths, we will also tag their NHS records to ensure we
capture any cardiac- and non-cardiac-related deaths be-
tween baseline and the 8-month follow-up. At the last
follow-up we will also request that the date and last re-
corded known cardiac risk factors in CCRP records are
extracted. At the same time we will contact the partici-
pant’s GP to request that they extract the same data
from primary care records, and that they summarise the
incidence of any new cardiac events, i.e. death and/or
hospital admissions for ACS or revascularisation proce-
dures (CABG or PCI), or mental health events (e.g. self-
harm, suicidality) arising since study enrolment. In
addition to being outcomes, these data will be part of
the safety monitoring of serious adverse events (SAEs)
and adverse events (AEs).
The baseline and follow-up interviews will include
self-reported cardiac- and non-cardiac- related morbid-
ity and smoking status, antidepressant medication use
[66], and resource use. Depressive symptoms will be
measured using the BDI-II [67, 68], a 21-item self-
report instrument measuring symptom severity with an
emphasis on affective and cognitive symptoms. Higher
scores represent greater depression severity (range 0–63),
and minimal (0–13), mild (14–19), moderate (20–28) and
severe (29–63) symptom severity ranges have been speci-
fied. The Beck Anxiety Inventory [69, 70] will be applied
as anxiety is commonly comorbid with depression. This
21-item, self-report measure asks patients to report anx-
iety symptoms over the last week from 0 (none: it did not
bother me at all), 1 (mildly: it did not bother me much), 2
(moderately: it was very unpleasant, but I could stand it),
and 3 (severely: I could barely stand it). Item scores are
summed with total scores of 8–15, 26–25, and 26–63
taken as cut-off points defining categories for mild,
moderate, or severe anxiety respectively. Health-related
quality of life will be assessed using both generic and
disease-specific measures. The 5-item EuroQoL (EQ-
5D) [71] is a standardised generic measure of health-
related quality of life, which is suitable for use in people
with a wide range of health conditions, and is recom-
mended by NICE for economic evaluations alongside
clinical trials. We will also administer the HeartQoL
[72, 73], a tool comprising 14 items, with 10-item phys-
ical and 4-item emotional subscales, which are scored
from 0 (poor health-related quality of life) to 3 (better).
To assess when and how participants become activated
over the course of their EPC, we will administer the 9-
item Behavioral Activation for Depression Scale – Short
Form (BADS-SF) [74] at baseline, and the 5-month and
8-month follow-up assessments. The BADS-SF is a 9-
item tool, where each item is rated from 0 (not at all)
to 6 (completely). The total score ranges from 0 to 54,
with high scores representing greater activation. Finally,
participant experiences of care will be assessed at the
5-month follow-up only, using the 8-item, self-reported
Client Satisfaction Questionnaire (CSQ-8) [75] and an
adapted version of the NHS Friends and Family Test
(FFT). The CSQ items use a 4-point Likert scale (1 to
4) response set, with the total scores ranging from a
possible 8 to 32; and higher values indicating greater
satisfaction. The FFT consists of a single item with a 5-
point rating scale (‘Extremely likely’ to ‘Extremely un-
likely’) and two free-text items (‘What was good about
your experience?’ and ‘What would have made your ex-
perience better?’).
Economic evaluation
The analytical perspective of NICE’s decision-making is a
societal costing perspective. The pilot study will test
methods of resource and service use data collection enab-
ling estimation of the costs to the NHS, costs to social
care and PSS, and relevant costs to patients and their
carers/families (including NHS and privately funded men-
tal health care). Wherever feasible, these will distinguish
use of services for (1) depression or anxiety; (2) for other
mental health problems; (3) for other health reasons or so-
cial needs. A preliminary assessment of the cost of provid-
ing EPC within CR will be undertaken. Service use data
will be collected from routine/administrative sources (e.g.
hospital records, GP records, community mental health
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team records, social care records) and participant self-
report using the Service and Resource Use Questionnaire
(SRUQ). The SRUQ will be adapted from the Client
Services Receipt Inventory [76], with input from our lay
advisors. The completeness, validity and reliability of
participant-reported versus routine administrative data
will be compared in relation to the types/amounts of
health care/service used over the follow-up periods
planned for a definitive trial.
Statistical analysis plan
Trial data will estimate CR team recruitment and pa-
tient study completion rates. As this is a pilot study we
will not report definitive estimates of effectiveness and
costs; our primary aim is to document the adequacy of
trial procedures, intervention acceptability and out-
come measures. All pilot study data will be collected
[77] and reported according to the CONSORT exten-
sion for cluster randomised trials [78]. Recruitment,
intervention and control uptake, outcome completion
rates, and drop out will be reported (with 95 % CIs).
We will compare the recruitment rate and participant
characteristics at baseline between the trial arms to as-
sess whether there is evidence of selection bias result-
ing from (cluster) randomising teams before participant
recruitment [79]. Patient outcome data (including re-
source use) will be analysed descriptively (e.g. means,
standard deviations (SDs)) for each arm at each follow-
up and we will report outcome effect sizes (i.e. between-
group mean differences and 95 % CIs) based on an
intention-to-treat analysis. We will explore the impact of
patient preferences documented at baseline in the analysis.
We will also conduct an exploratory sensitivity analysis
reporting between-group outcomes in the sub-groups of
patients who do, or do not attend, cardiac rehabilitation
programmes.
Qualitative interview study
Data collection
Several methods of data collection will be used. The re-
searcher will observe staff training to identify what is-
sues nurses appear to struggle with and what practical
concerns they have about EPC. Observations will be re-
corded through extensive field notes. Nurses trained in
EPC will be invited to take part in an interview towards
the end of EPC delivery (once they have gained experi-
ence in delivering the intervention), to explore their
views on the nurse manual, and to assess their views
and experiences of delivering EPC within existing pro-
grammes. These interviews will be held by an experi-
enced qualitative interviewer (RW) following a topic
guide. Interviews will be conducted either by telephone or
on a face-to-face basis, as the teams will be based across a
large geographical area and telephone interviews can be
used to gather the same material as those held face-to-
face [80]. Written consent will be secured from those
interviewed in person and verbal consent will be gained
from those interviewed by telephone. It is predicted that
up to 15 nurses will be involved in delivery of EPC in the
five CCRPs allocated to the intervention arm. The aim will
be to interview around 10 of these nurses.
In-depth interviews will be conducted with patients re-
cruited to the trial who subsequently agree to take part
in qualitative interviews. When sampling these patients
we will aim for maximum variation in relation to trial
arm, age, CR team, gender, socio-economic background,
depression score at baseline and adherence to the inter-
vention. Participants will be interviewed shortly after
they have completed their 5-month follow-up measure-
ments in case the interview process influences their
views of the intervention or trial. Participants will be
given an opportunity to ask questions before the inter-
view takes places, and written informed consent will be
obtained prior to commencing. All interviews will be
conducted by RW following a topic guide. Individuals
will be interviewed by telephone or on a face-to-face
basis, and verbal or written consent secured respectively.
It is predicted that about 30 participants recruited to the
trial will be interviewed (10 usual care, 12 completers
and 8 non-completers of EPC).
Interviews will also be held with patients who declined
to take part in the trial to identify reasons for their deci-
sion. These interviews will usually be held by telephone
to encourage participation. The data gathered will indi-
cate ways to maximise recruitment and to reflect upon
how representative individuals in the trial are of other
CR patients. About 10 ‘decliners’ will be interviewed
early on in the trial.
Qualitative analysis plan
Data collection and analysis will proceed in parallel. All
interview data will be audio-recorded, transcribed verba-
tim and analysed thematically with the aid of NVivo,
and using an approach based on a framework approach
[81]. Analysing the data thematically will enable compar-
isons to be made within and across the interviews, and
for the views of staff and patients to be compared and
contrasted regarding specific topics, such as intervention
acceptability.
Ethical and governance considerations
The Royal Devon and Exeter NHS Foundation Trust is
acting as the trial sponsor. This paper describes the
CADENCE study protocol (version 4, 19 June 2015),
which was reviewed and a favourable ethical opinion
obtained from the National Research Ethics Service
(NRES) Committee South West – Exeter (reference: 14/
SW/0139) and the relevant NHS research governance
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approvals were obtained prior to commencing fieldwork
from: the Royal Cornwall Hospitals NHS Trust; Somerset
Partnership NHS Foundation Trust; Taunton and Somer-
set NHS Foundation Trust; Torbay and South Devon
NHS Foundation Trust; University Hospitals Bristol
NHS Foundation Trust; University Hospitals Coventry
and Warwickshire NHS Trust; Weston Area Health
Trust; and Yeovil District Hospital NHS Foundation
Trust. Any protocol amendments will be notified through
existing pathways in the UK NRES and NHS research gov-
ernances system, and the trial team will ensure that all
participating CCRPs, staff and patients, and trial registries
are informed of any changes to the protocol.
This study is registered with a trials registry
(ISRCTN34701576) and has been adopted by the UK
Comprehensive Research Network (UKCRN ID: 17105).
All researchers and nurses involved in participant recruit-
ment will undertake Good Clinical Practice (GCP) training.
Data management
All personal information obtained about patients or staff
for the purposes of recruitment or data collection will be
held in accordance with the UK Data Protection Act,
1998. Each participant will be assigned a research num-
ber and all outcome data will be encrypted and stored
without the participant’s name or address. Electronic
study records will be stored in a SQL server database
managed by the Peninsula Clinical Trial Unit (PenCTU),
hosted on a secure server maintained by Plymouth Uni-
versity. Access to electronic data will be permission-
based, with access to identifiable information limited to
those processing questionnaires and performing initial
screening activities. Copies of study data retained at par-
ticipating sites will be securely stored for the duration of
the study prior to archiving. Electronic copies of any let-
ters or e-mails sent to study participants will be stored
securely on a password-protected computer at the Uni-
versity of Exeter, and paper-based information held in a
locked filing cabinet in the research team offices. Names
and participant details will not be passed onto any third
parties and no named individuals will be included in the
write-up of the results. The only time personal informa-
tion would be passed on to a third party (i.e. the patient’s
GP) would be if we considered there to be risk of serious
harm to a research participant and safety protocols need
to be activated.
All study data will be kept for 10 years under secure
conditions on University of Plymouth and University of
Exeter servers. We will seek consent from participants
for core outcome data from the pilot study to be re-
leased in an anonymised form to an independent data
repository (for example, the UK Data Archive) following
publication of the key planned outcome papers.
Safety of participants and researchers
While we believe the study has minimal implications for
health care staff, participants will have been found to
have depressive symptoms and it is, therefore, appropri-
ate to have a safety policy in place regarding the man-
agement of potentially serious adverse events (e.g. self-
injury or suicidality). The Participant Information Sheet
will let the person know that if we are very concerned
about their safety or someone else’s safety we may need
to break confidentiality and inform their GP.
Involvement in research interviews where participants
are asked to reflect on their health issues can, in some
cases, cause distress. Should any such difficulties occur
during a research interview, the researcher will offer
support to the person involved. Should a participant ap-
pear significantly upset and at risk as a result of the
interview, the researcher will (with permission) advise
the individual’s GP of this distress and encourage the
person to seek further support from the support network
available to them. Should there be any concern that a
participant is likely to cause harm either to themselves
or another person, their GP will be notified immediately
by a senior clinician from the study team. Since re-
searchers will be conducting interviews alone with par-
ticipants, potentially in the participant’s own home, it
will be important to have safeguards in place to protect
both participant and researcher. Disclosure and Barring
Service checks will be performed on any researcher tak-
ing part to ensure that they are an appropriate person to
be working with vulnerable adults. To ensure the safety
of researcher and patient, a lone-worker policy will be
applied, providing a mechanism for ensuring that the
exact whereabouts of researchers and patients engaged
in research activities is known.
Patient and public involvement
Patient and public involvement (PPI) has been sought
during protocol development. The NIHR CLAHRC for
the South West Peninsula (PenCLAHRC) hosts the Pen-
insula PPI Group (http://clahrc-peninsula.nihr.ac.uk/pa-
tient-and-public-involvement-in-research). This group
has published a framework regarding PPI involvement in
research [82], and provides research training and sup-
port to facilitate the public becoming actively involved
in all aspects of the research process. The co-applicant
(AG, PPI facilitator) recruited four lay advisors with rele-
vant, lived experience, each of whom reviewed and
commented on our research proposal. PPI will con-
tinue throughout this project, with the precise roles of
advisors negotiated across time. In the early stage, our
lay advisors reviewed outcome measures and informed
the design of all study-related materials, e.g. informa-
tion sheets and consent forms. Our lay advisors were
also involved in the development of the intervention
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and accompanying training manual. This helped en-
sure the acceptability of the intervention to patients.
Four lay advisors also attend our project management
meetings on a quarterly basis and actively participate
in decisions related to the ongoing running of the pro-
ject. A key area of future involvement will be in dis-
semination plans. Our lay advisors will work with us
to proactively shape the BACPR standards, ensuring
that the needs of patients with depression are embed-
ded within the core service descriptions. When sitting
on committees, lay advisors will have equal voting
rights compared with academic/clinical members. Lay
advisors will be paid costs for travel and for time spent
at meetings in line with INVOLVE guidance on good
practice. AG will support lay advisors attending meetings
and/or identify appropriate training opportunities. This
will maximise the ability of our lay representatives to ac-
tively contribute to our work.
Project oversight
JC (chief investigator) and SR (scientific lead) will
supervise and oversee the strategic development and
progress of the project, liaising with the wider team and
methodological leads on a routine basis. All research fel-
lows will be based in Exeter (with JC and SR) and will
manage the day-to-day aspects of the research relevant
to their own role, supported by an administrator at peak
periods of fieldwork activity. KT will provide qualitative
expertise and supervision, RA is the health economics
lead, OCU is the statistics lead, and AG will lead PPI en-
gagement. Monthly project management meetings will
be organised to ensure co-applicants and two lay advi-
sors are kept informed of progress and contribute to the
ongoing steering of the research.
As this is a pilot trial, a data monitoring committee
has not been convened. A Trial Steering Committee
(TSC) with independent chair will be appointed in ac-
cordance with MRC guidelines. Members will represent
an appropriate range of perspectives and expertise (e.g.
two lay advisors, clinicians, methodologists), meeting at
critical points in the project timeline. The TSC will
monitor the scientific quality, ethics and general pro-
gress of the project, and will monitor the SAE/AE data
emerging from the study.
Project timeline
The project commenced on 1 April 2014 and is sched-
uled to complete in July 2016. The feasibility study was
reported in May 2015. Preparatory work for the pilot
trial, including CR team recruitment, commenced January
2015. Cluster randomisation took place in April 2015, and
intervention training delivered to the five CR teams in
June–July 2015. Participant recruitment commenced July
2015 and is scheduled to complete by the end of 2015.
Follow-up data and qualitative interviews will take place
between September 2015 and June 2016. Data analysis will
commence in January 2016, with the final report due in
July 2016.
Discussion
This paper presents the study protocol (version 4, 19
June 2015) for the CADENCE study, reported to satisfy
the Standard Protocol items: Recommendations for
Interventional Trials (SPIRIT) guidelines (Additional
file 2). This study will provide important information
supporting the development and subsequent evaluation
of psychological treatment for patients identified with
depressive symptoms following an ACS or revasculari-
sation procedure. Our EPC intervention involves train-
ing CR nurses in the application of evidence-based
mental health care co-ordination algorithms, and in
how to actively support and monitor patients working
through a BA self-help manual with associated tasks.
While both mental health care co-ordination and BA
have previously been demonstrated to be effective treat-
ments for patients with depression, their application to
busy CR settings and patients is untested. A crucial
element of this research will be to examine the feasibil-
ity and acceptability of implementing mental health
care management strategies within the routine care.
Study outcomes will inform the design of a definitive
clinical trial that will provide evidence of the effective-
ness, cost-effectiveness and acceptability of embedding
psychological care within the CR care pathway.
This study was funded in response to a commission-
ing brief from the Health Technology Assessment
board of the UK the National Institute for Health Re-
search (NIHR; project reference 12/189/06), which
identified this research area as an important knowledge
gap and which sought to investigate an intervention
embedded within routine care. We will disseminate our
findings widely, to ensure this research will guide
policy-makers and clinicians in the future development
and organisation of psychological care for patients with
depressive symptoms engaging with CR services. We
anticipate that data on acceptability will be of immedi-
ate interest to patients and their families, professionals
responsible for the design and implementation of CR
services, and to the professional body (BACPR) respon-
sible for defining core services and standards of care
within NHS CR services.
Trial status
Patient participant recruitment commenced in July
2015 and is ongoing, scheduled for completion in
December 2015.
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Additional files
Additional file 1: Guide for session planning for nurses delivering
enhanced psychological care as part of a comprehensive cardiac
rehabilitation programme. (DOCX 44 kb)
Additional file 2: SPIRIT Checklist: CADENCE study protocol
(version 4, 19 June 2015). (DOCX 61 kb)
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